Profiel
André van Puijenbroek is Manager of Research and Development for InteRNA Technologies BV.
Prior to joining InteRNA Technologies, he was a Group Leader of Organon BioSciences, Inc. for Immunology from 2002 to 2005 and for Oncology from 2005-2008 .
He joined InteRNA Technologies as Project Manager of Research and Development in November 2008.
Prior to it, he worked as a Post-Doctoral Research Fellow Member at the Netherlands Cancer Institute from 1997 to 1999 and the Dana-Farber Cancer Institute at Harvard Medical School from 1999 to 2002.
Dr. van Puijenbroek received an MSc degree in Biology in 1992 and a PhD in Molecular Biology in 1997 from Utrecht University.
Eerdere bekende functies van André van Puijenbroek
| Bedrijven | Functie | Einde |
|---|---|---|
| Organon Biosciences, Inc. | Corporate Officer/Principal | 01-01-2005 |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van André van Puijenbroek
| University of Utrecht | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Health Technology |
| Organon Biosciences, Inc. |
